T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases

被引:40
|
作者
Zagon, Ian S. [1 ]
Donahue, Renee N.
Bonneau, Robert H. [2 ]
McLaughlin, Patricia J.
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Neural & Behav Sci, Coll Med, Hershey, PA 17033 USA
[2] Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA USA
关键词
Cell proliferation; Cyclin dependent kinase inhibitor; Met(5)]-enkephalin; Opioid growth factor; OGFr; T lymphocyte; SQUAMOUS-CELL CARCINOMA; BETA-ENDORPHIN; METHIONINE-ENKEPHALIN; PROENKEPHALIN-A; STABLE OVEREXPRESSION; ENDOGENOUS OPIOIDS; PANCREATIC-CANCER; MESSENGER-RNA; EXPRESSION; PEPTIDES;
D O I
10.1016/j.imbio.2010.09.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Opioid peptides function as immunomodulatory molecules. Reports have linked the opioid growth factor (OGF), [Met(5)]-enkephalin, and its receptor OGFr to autoimmune diseases. OGF repressed the incidence and magnitude of myelin oligodendrocyte-induced experimental autoimmune encephalomyelitis in mice. Given the extensive connection between the immune system and autoimmune diseases, the present study was conducted to examine the relationship of the OGF-OGFr axis and T lymphocyte proliferation. Splenic-derived mouse lymphocytes were stimulated with phytohemagglutin (PHA). All non-stimulated and PHA-stimulated T lymphocytes had immunoreactivity for OGF-like enkephalin and OGFr. OGF markedly suppressed T lymphocyte number in a dose-dependent manner. However, PHA-stimulated T lymphocytes were not altered in cell number by a variety of natural and synthetic opioid-related compounds, some specific for mu, delta and kappa opioid receptors. Persistent blockade of opioid receptors with the general opioid antagonist naltrexone (NTX), as well as antibody neutralization of OGF-like peptides, had no effect on cell number. Non-stimulated T lymphocytes exhibited no change in cell number when subjected to OGF or NTX. Treatment of T lymphocytes with siRNAs for mu, delta or kappa opioid receptors did not affect cell number, and the addition of OGF to these siRNA-exposed cultures depressed the population of cells. T lymphocytes treated with OGFr siRNA also had a comparable number of cells to control cultures, but the addition of OGF did not alter cell number. DNA synthesis in PHA-stimulated T lymphocytes exposed to OGF was markedly decreased from PHA-stimulated cultures receiving vehicle, but the number of cells undergoing apoptosis or necrosis in these cultures was similar to control levels. T lymphocytes subjected to siRNA for p16 and/or p21 had a comparable number of cells compared to controls, and treatment with OGF did not depress cell number in preparations transfected with both p16 and p21 siRNA. These data reveal that the OGF-OGFr axis is present in T lymphocytes and is capable of suppressing cell proliferation. However, T lymphocytes are not dependent on the regulation of cell proliferation by this system. The results showing that the OGF-OGFr axis is an immunosuppressant, offers explanation for reports that autoimmune diseases can be modulated by this system. (C) 2010 Elsevier GmbH. All rights reserved.
引用
收藏
页码:579 / 590
页数:12
相关论文
共 50 条
  • [1] B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases
    Zagon, Ian S.
    Donahue, Renee N.
    Bonneau, Robert H.
    McLaughlin, Patricia J.
    [J]. IMMUNOBIOLOGY, 2011, 216 (1-2) : 173 - 183
  • [2] An opioid growth factor receptor (OGFR) for [Met5]-enkephalin in Chlamys farreri
    Guo, Ying
    Wang, Lingling
    Zhou, Zhi
    Wang, Mengqiang
    Liu, Rui
    Wang, Leilei
    Jiang, Qiufen
    Song, Linsheng
    [J]. FISH & SHELLFISH IMMUNOLOGY, 2013, 34 (05) : 1228 - 1235
  • [3] Modulation of the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck
    McLaughlin, Patricia J.
    Stucki, Jaimon K.
    Zagon, Ian S.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2012, 34 (04): : 513 - 519
  • [4] Transplacental transfer of the opioid growth factor, [Met5]-enkephalin, in rats
    Zagon, IS
    Wylie, JD
    Hurst, WJ
    McLaughlin, PJ
    [J]. BRAIN RESEARCH BULLETIN, 2001, 55 (03) : 341 - 346
  • [5] The autocrine derivation of the opioid growth factor, [Met5]-enkephalin, in ocular surface epithelium
    Zagon, IS
    Sassani, JW
    Wu, Y
    McLaughlin, PJ
    [J]. BRAIN RESEARCH, 1998, 792 (01) : 72 - 78
  • [6] Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]enkephalin
    Zagon, IS
    Verderame, MF
    Allen, SS
    McLaughlin, PJ
    [J]. BRAIN RESEARCH, 1999, 849 (1-2) : 147 - 154
  • [7] Ontogeny of the opioid growth factor, [Met5]-enkephalin, preproenkephalin gene expression, and the ζ opioid receptor in the developing and adult aorta of rat
    Wu, Y
    McLaughlin, PJ
    Zagon, IS
    [J]. DEVELOPMENTAL DYNAMICS, 1998, 211 (04) : 327 - 337
  • [8] Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation
    Cheng, Fan
    McLaughlin, Patricia J.
    Banks, William A.
    Zagon, Ian S.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2010, 299 (03) : R774 - R785
  • [9] Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy:: maternal and preweaning effects
    McLaughlin, PJ
    Wylie, JD
    Bloom, G
    Griffith, JW
    Zagon, IS
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 71 (1-2) : 171 - 181
  • [10] Stability of opioid growth factor ([Met5]-enkephalin) in solution using HPLC and photodiode array detection
    Hurst, WJ
    McLaughlin, PJ
    Zagon, IS
    Rogosnitzky, M
    [J]. JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2006, 29 (02) : 151 - 157